[Treatment of infantile parotid hemangioma with propranolol].
OBJECTIVE
To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma.


METHODS
Oral propranolol was administered to 17 infants with parotid hemangioma at a dose of 1.0-1.5 mg per kilogram of body weight per day. The patients were revisited once a week. The changes of the tumor size, texture and colour were monitored and recorded at a regular interval. The adverse effects after medication were observed and managed accordingly. The short-term results were evaluated using a 4 scales system.


RESULTS
Among the 17 patients treated, the follow-up time was 5 to 10 months. The overall response was scale I in 0 patient, scale II in 0 patients, scale III in 5 patients, and scale IV in 12 patients. No serious adverse effects were encountered.


CONCLUSIONS
Oral propranolol at a lower dose is a safe and effective method for the treatment of infantile parotid hemangioma. The short-term results were excellent and the side effects minimal.
Liu
Xue-jian
XJ
Department of Hemangioma, Tumor Hospital of Linyi City, Linyi Shandong 276000, China.
Qin
Zhong-ping
ZP
Tai
Mao-zhong
MZ
Li
Ke-lei
KL
Ge
Chun-xiao
CX
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D010307:Parotid Neoplasms / Q000188:drug therapy*; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol